Navigation

Appeal Panel membership

Click the committee member name below to go to their biography.

Dr Margaret Helliwell

Vice Chair (Chair of the Appeal Committee)

Professor David Hunter

Non-Executive Director

Professor Rona McCandlish

Non-Executive Director

Mr Andy McKeon

Non-Executive Director

Professor Finbarr Martin

Non-Executive Director

Mr Bill Mumford

Non-Executive Director

Ms Linda Seymour

Non-Executive Director

Mr Jonathan Tross

Non-Executive Director

Mr Uday Bose

Industry representative

Dr Mark Chakravarty

Industry representative

Dr Catriona McMahon

Industry representative

Dr Mercia Page

Industry representative

Dr David Gillen

Industry representative

Mr Patrick Hopkinson

Industry representative

Mr Peter Dransfield

Lay representative

Dr Jonathan Fear

Lay representative and Appeal panel chair

Dr John Morris

Lay representative

Mr Bob Osborne

Lay representative

Mr Peter Sanders

Lay representative

Professor Alan Silman

Lay representative and Appeal panel chair

Mr Colin Standfield

Lay representative

Mr Patrick Storrie

Appeal Panel chair and Patient representative

Dr Robert Thurstans

Lay representative

Dr Marios Adamou

NHS representative

Professor Robin Ferner

NHS representative

Dr Frank McKenna

Appeal panel chair and NHS representative

Dr Anthony Emmerson

NHS representative

Dr Ashutosh Wechalekar

NHS representative

Mr Uday Bose, Industry representative

Uday Bose has been a member of the Appeal Committee since 2011. He is currently European Business Unit Head for Eisai's hospital speciality products. He has extensive commercial experience from senior roles in organisations such as GSK and Sanofi-aventis, but started his career in the industry as a health economist. Over the years Uday has developed significant HTA experience, primarily in the UK but also through his Global roles.

Back to top

Dr Mark Chakravarty, Industry representative

Mark holds a degree in Pharmacology and qualified in Medicine at the University of Manchester, UK, in 1995. He then held various hospital appointments in clinical medicine before taking a joint Medical Adviser post with the NHS Executive in the North West and the Post-Graduate Medical Deanery in Manchester. During this time Mark was the Chairman of the Northwest Junior Doctors Committee, executive member of the National Junior Doctors Committee of the British Medical Association, and a national negotiator for Junior Doctors. He then studied business at Manchester Business School before joining Procter & Gamble, in 1999, as a Medical Advisor for Cardiology. His interests include health/science communication, health outcomes, the role of the consumer in health care, crisis leadership and communication. Mark has been a member of the National Institute for Health and Care Excellence (NICE) Appraisals Committee from 2003 to 2012. He has also participated in a number of exploratory areas of the NICE programme, including the Patient Safety Assessment conducted between NICE and the National Patient Safety Agency, the NICE Topic-specific Advisory Group to develop a Commissioning Guide for Biologic Drugs and NICE's feasibility study for the assessment of ultra-orphan diseases. Mark has previously been a member of the Public Relations & Economic Committee of the Association of the European Self-Medication Industry (AESGP) and World Self Medication Industry Association's Task Force on Risk/Benefit. Mark is currently the Communications Director Procter & Gamble- Global Baby, Feminine & Family Care.

Back to top

Dr Catriona McMahon, Industry representative

Catriona McMahon has been a member of the Appeal Committee since 2011. She joined AstraZeneca PLC in 1998 and has held various increasing leadership roles within Medical Affairs in the United Kingdom (UK), including the positions of Medical Head Specialist Care, acting Medical & Regulatory Affairs Director, and Head of AstraZeneca's UK Clinical Research Group. She worked as an industry representative with the UK National Institute for Health and Clinical Excellence (NICE) for two years, and sat as one of the industry partners within the UK Clinical Research Collaboration in 2007, working closely with the UK Department of Health and National Health Service (NHS) R&D in the development of the UK Clinical Research Network.

In March 2008, Dr. McMahon was promoted to Vice President, Medical Affairs for AstraZeneca Canada. In Canada, she sat on the Advisory Board to the President of Canadian Institute for Health Research , and was closely involved in the development of key national strategies, focusing on Patient Orientated Research. In addition, she sat on the Scientific Committee of the Canadian Consortium for Research and Development of Medicines, the Scientific Committee of Health Research Foundation of Rx&D, and the Board of Directors of Quebec Consortium for Drug Discovery and the Centre of Excellence for Personalised Medicine. She was Chairperson for the Rx&D Medical/Clinical Subcommittee. In June 2010, Dr. McMahon transferred back to AZUK as Medical and Regulatory Affairs Director.

Dr. McMahon graduated from Edinburgh University Medical School, and trained in Anaesthesia and Critical Care Medicine in the North-East of England. She gained Fellowship of the Royal College of Anaesthetists (UK) in 1994, and Membership of the Faculty of Pharmaceutical Medicine, Royal College of Physicians, England, in 2001.

Back to top

Dr Mercia Page, Industry representative

Mercia Page has been a member of the Appeal Committee since 2011. She qualified in medicine from Kings College Hospital Medical School and spent 8 years in hospital practice in the NHS, before joining the pharmaceutical industry. She gained experience in clinical research and specialised in pharmaceutical medicine. She also completed an MBA from Ashridge in 2001. Dr Page joined NICE in Autumn 2003 as the Associate Director for the Guidelines Programme, and became the Director of the Centre for Clinical Practice. Mercia has been Director of Medical Affairs at MSD Ltd since April 2008. She was appointed to SMC as an industry member in April 2009.

Back to top

Dr David Gillen - Industry representative

Dr David Gillen (BSc MD FFPM) has been a member of the Appeal Committee since 2012. He is Medical Director for Celgene UK and Ireland. Prior to this role he was Head of International Medical Affairs for Gilead Sciences where he managed and led a group of Medical Directors across Europe and Asia-Pacific. Before this he was Vice President Medical Affairs for the Pfizer Primary Care Business Unit covering Europe, Canada, Australia and New Zealand where he established a regional medical affairs group covering Pfizer's primary care portfolio of medicines.

David qualified in Medicine from St Mary's Hospital in 1992. During his undergraduate medical training he completed a BSc in Physiology and Clinical Pharmacology. He retained this interest in Pharmaceutical Medicine during his postgraduate training in Medicine, Cardiology and General Practice and joined Pfizer Global Research and Development in Sandwich in 1998. At Pfizer, David has worked in R&D and in Medical Affairs for the UK and in New York for 4 years. David is passionate about and active in the UK Clinical Research community, most recently being part of the Academy of Medical Sciences working group looking into Streamlining UK Clinical Research Governance.

Beyond clinical research, David has served on the Innovation Sub-committee of the ABPI (Initiating the ABPI Real - World data project), has worked at NICE and the UKCRC and was a member of the RCP working party looking at the relationship between industry, academic medicine and the NHS.

Back to top

Mr Patrick Hopkinson, Industry representative

Patrick is Director of Market Access and External Affairs at Bristol Myers Squibb. In his role Patrick leads the key market access functions including Government Affairs, Communications, Pricing , Pharmacy & Distribution and Health Economics and Outcomes Research.

He manages the strategic and operational interfaces with UK HTA bodies (ie NICE, SMC and AWMSG), the NHS, Department of Health and Government. He represents BMS on a number of Industry bodies including the ABPI Value and Uptake Group and the American Pharmaceutical Group. He Chairs the ABPI Pharmaceutical Stroke Prevention in Atrial Fibrillation Initiative. Previously he was involved in a number of key Life Science policy initiatives including the ABPI/DoH Joint Working Task Force, the Office of Life Science Blue Print and the QIPP National Initiative.

Patrick joined BMS in Sept 2010. Previously he had spent 14 years at GSK in a variety of roles. He joined as a health economist in R&D, moved rapidly to a global strategic marketing role before moving to GSK UK. Following roles in sales management and marketing he was appointed Business Unit Director for the Specialist portfolio and finally appointed Director Portfolio and Partnership Marketing a key strategic department pioneering innovative projects with the NHS.

Prior to GSK, Patrick worked as a Clinical Pharmacist for 8 years specialising in Oncology and Palliative Care. Initially at Guys and St Thomas' London and then Royal Berkshire Hospital Reading. He holds a Diploma in Clinical Pharmacy, a Masters in Health Economics and a MBA from Henley Management School.

Back to top

Mr Peter Dransfield, Lay representative

Peter Dransfield has been a member of the Appeal Committee since 2006. Peter holds an M.B.E. which was awarded in the 1999 New Year's Honours list, for service to the Community. Peter is a retired Principal Local Government Officer, after 34 years Service. When He retired he left the position of Principal Committee Secretary in the Office of the Chief Executive with Kirklees Metropolitan Council. He served for 22 years as a member appointed by the Lord Chancellor on the Social Security Benefits Appeals Tribunals. Peter is a school Governor of a very large Technology College. He was for a time following retirement, the Town Clerk for the local Town Council, and is currently a Trustee on two Almshouses Trustee Boards and Chairman of one of them. He also acts as Secretary/Treasurer to many organisations, both local, National and International, and is a Church of England Chorister.

Back to top

Dr Jonathan Fear, Lay representative and Appeal panel chair

Dr Fear is an experienced Consultant in Public Health Medicine having provided senior public health leadership in a variety of organisations and settings, including Board level responsibility as Director of Public Health for Leeds West Primary Care Trust. Most recently he was Head of Health Care Effectiveness and Deputy Director of Public Health for NHS Leeds. At the end of 2012 he retired from the NHS but continued to chair the Leeds Clinical Commissioning Groups' Individual Funding Request panels on a consultancy basis and provide Leeds Clinical Commissioning Groups with advice on policy development.

Between 2002 and 2006 he was Director of Public Health at Leeds West PCT, responsible for the recruitment and development of a team of 34 staff (100 including Prison Healthcare staff) and accountable for a budget of about £25 million.

In his last NHS role he provided public health leadership to the planned urgent screening and specialist services integrated commissioning team for NHS Leeds and was the public health lead for one of the GP consortia and NHS Leeds corporate leadership team. He was Deputy Director of Public Health and public health lead and board member for Leeds South and East Clinical Commissioning Group.

He was a member of NICE Technical Appraisal Committee D for 3 years and chaired the IFR panels in Leeds since 2006.

Back to top

Dr John Morris, Lay representative

John Morris has been a member of the Appeal Committee since 2011. Dr Morris's career began in pharmaceutical and crop protection scientific research. During this time he also developed an interest and expertise in psychodynamic counselling and interpersonal skills training. He then took these varied experiences and skills to the voluntary sector, managing information, support and advocacy services in two health charities, covering haemophilia and thrombosis and associated conditions such as hepatitis C and HIV.

Membership of another charity's advisory panel, the Long-term Medical Conditions Alliance and Patients in NICE gave him a broader understanding of the needs of people living with medical conditions. Having twice been a patient expert on hepatitis C NICE technology appraisals, he then joined the Royal College of Physicians to project manage the development of NICE clinical guidelines, primarily working on the COPD update. Most recently, he applied his ability of ‘translating' complex medical information into lay language to writing training materials on a host of healthcare subjects, and continues to support the UK's first gene therapy trial for haemophilia as its patient ombudsman.

He is passionate about empowering people to be self-managers of their health conditions and to participate fully in locally and national decision-making about NHS service provision. In particular, he is committed to ensuring the patient/carer voice is heard at all stages of the TA process.

Back to top

Mr Bob Osborne, Lay representative

Bob Osborne has been a member of the Appeal Committee since 2006. Bob joined the Royal Air Force in 1960 and following pilot training was employed mainly on transport aircraft. In 1970 he qualified as a flying instructor and then continued as a training captain on Hercules aircraft flying global routes and specialising in low level operations with air drops of parachutists and equipment.

His final service posting was to the RAF Institute of Aviation Medicine at Farnborough in the Behavioural Psychology division. Here he managed to combine flying with acting as a straight man for the psychologists and being the subject of various and usually uncomfortable trials.

On leaving the RAF he joined Laker Airways and flew DC10's until the company's demise in 1981. He then worked for an American carrier in New York, spent six months with a Bangladesh Airline and returned to the UK in 1986. He flew for British and Italian companies in the charter and scheduled market until retirement at age sixty. Interestingly, with one airline he was involved in setting up the training programme for crews known as Crew Resource Management which is now being considered for use in the NHS.

Two years were then spent in retirement with an Advocacy project funded by the lottery where he acted for people unable to represent themselves. He was selected to be a member of the first Citizens Council with NICE and following that, was selected for the Technology Appraisals Appeals Panel.

He is married with two daughters, one of whom has pre-deceased him, and five grandchildren. He is the chairman of the local branch of The Aircrew Association, a retired servicemans' organisation. He therefore retains a continuing interest in the medical and social welfare of veterans.

Back to top

Mr Peter Sanders, Lay representative

Peter Sanders has been a member of the Appeal Committee since 2006. Peter E Sanders is a Manufacturing Consultant who advises businesses on how to improve performance. He currently holds a number of Non-Executive Company Directorships.

Since the mid-nineties Peter has volunteered time to advising various Charities with their strategic planning, operations and funding. In 2000 Peter joined The Nye Bevan NHS National Awards Committee and the Lay Advisory Group to the Faculty of General Dental Practice (UK) at the Royal College of Surgeons of England and later becoming Chairman of this Group.

Peter is a Magistrate, a Complaints Panel Member of the Dental Complaints Service and an Independent Chairman of an Agricultural Dwelling House Advisory Committee.

Peter is also interested in social housing and he is currently Vice Chairman of a Housing Society.

Back to top

Professor Alan Silman, Lay representative and Appeal panel chair

Alan is responsible for providing the strategic direction and leadership to our research and education activities. He has been involved in medical research in the musculoskeletal field for the past 30 years, and prior to joining Arthritis Research UK was Director of the (then) arc's Epidemiology Unit (1988-2006). Until the end of 2011 Alan was a consultant rheumatologist at the Manchester Royal Infirmary.

Some of his milestones include leading the Epidemiology Unit to its award as the European League Against Rheumatism (EULAR) Centre of Excellence in 2006; he was Heberden Orator in 2004; he received Honorary Doctorates from UEA in 2009 and Keele University in 2012. Alan is the UK editor of the main leading international textbook ‘Rheumatology' and is a distinguished speaker both in the UK and overseas.

His external responsibilities include membership of the MHRA Pharmacovigilance Expert Advisory Group; Chairman of the Assessment Panels of UK Universities Research Assessment Exercise (2002-2008); and Chairman, Ministry of Defence panel of research into the health of servicemen and women. He chaired the NICE panel on local formularies 2012 and convened a round table workshop with NICE in 2009 to identify how Arthritis Research UK as a research organisation could work with NICE both to enhance quality of evidence base for the TA's as well as follow up when there are NICE research recommendations.

Back to top

Colin Standfield, Lay representative

Colin Standfield has been a member of the Appeal Committee since 2011. Colin is an Oxford MA in English and has a background at Board level in advertising and marketing. He also has a long association with substance misuse issues and worked for 10 years as a Trustee and then Development Officer with Battling Addictions Together, a user-led Ealing charity helping people recover from drug and alcohol problems. He is a Trustee of Drugscope and has been involved with a number of Ealing and pan-London committees in the field, including the Ealing Drug and Alcohol Task Group and the Greater London Alcohol and Drug Alliance. He is Church Council Secretary and a former Senior Steward at Hanwell Methodist Church. He is a skilled presenter and has experience of service improvement within the NHS; he has run redesign programmes for Substance Misuse and Mental Health teams in boroughs across the country. Colin was the elected Chair of the Ealing and West London Research Ethics Committee for over four years and was a Non-Executive Director of Ealing Primary Care Trust from 2004 to 2007.

Back to top

Paddy Storrie, Appeal Panel chair and Patient representative

Paddy Storrie is a History teacher and has been involved as a lay member with NICE since 2004, initially for four years as a member of the Citizens' Council, and since 2009 as a lay member on Appraisals Committee D. He sat in 2010-11 on the Academy of Medical Science Working Group on the Regulation and Governance of Medical Research. Paddy is a member of the MHRA Patient and Public Engagement Expert Advisory Group. He is on the Steering Committee of the High Intensity Specialist Led Acute Care research project, and has spoken twice at the Forum of Health Technology Appraisal International, a clearing house made up of representatives of regulators, payer bodies, and health technology businesses.

Back to top

Dr Robert Thurstans, Lay representative

Robert Thurstans has been a member of the Appeal Committee since 2011. Dr Thurstans spent his working life in physics research and teaching, specialising in solid state, in particular thin films. He has taught courses on physical methods of clinical diagnosis, served as a non executive director of an inner city Primary Care Trust, a patient liaison group member for the Royal College of Radiologists and an accreditor of radiology departments for the United Kingdom Accreditation Service.

Back to top

Dr Marios Adamou, NHS representative

Marios Adamou is a Consultant Psychiatrist in neurodevelopmental psychiatry (ADHD and ASD) at South West Yorkshire Partnership NHS Foundation Trust. He is the Head of Specialist Service Development and Foundation Trust Governor at the same organisation. He is a board member of the Governing body of East Ridings Clinical Commissioning Group. He holds offices at the Royal College of Psychiatrists where he is a member (MRCPsych). He is presently the Deputy Regional Advisor for the Yorkshire Region, elected member of the Executive Committee of the Faculty of General Adult Psychiatry whose is the policy lead, and co-opted member for the Northern and Yorkshire Division.

His Medical Training (MD) was completed at the Aristotle University, Thessaloniki, Greece and his Psychiatric training at Guys, Kings and St Thomas's scheme in London. He held full time research positions at the University of Kent and Institute of Psychiatry, London.

Marios has academic qualifications in a number of disciplines. He completed postgraduate degrees (MSc) in Mental Health Studies, MA (History), LL.M (Medical Law), MBA (Business Administration) and PGCE (Medical Education). He earned a postgraduate diploma in Occupational Medicine (DOccMed) awarded by the Faculty of Occupational Medicine of the Royal College of Physicians. He completed a PhD by research.

He is an International Fellow at the Centre for Innovation in Health Management at the University of Leeds and Executive Committee Member at the UK adult ADHD Network (UKAAN). He is the Chair of the Northern Adult ADHD Clinician's Group (NACG).

He is a Fellow of the Higher Education Academy (FHEA), the Royal Society of Arts (FRSA), the Royal Society of Public Health (FRSPH) and the Society of Biology (FSB). He is a founding member of the Faculty of Medical Leadership and Management. He is a Chartered Member of the Chartered Management Institute (CMgr MCMI).

Back to top

Professor Robin Ferner MSc, MD, FRCP, NHS representative

Robin Ferner has been a member of the Appeal Committee since 2006. Robin is a Consultant Physician and Clinical Pharmacologist, City Hospital, Birmingham.

Robin Ferner studied chemistry before qualifying in Medicine in 1978. Since 1990 he has been a consultant physician in Birmingham, with a particular interest in clinical pharmacology. He is Director of the West Midlands Centre for Adverse Drug Reactions, and Honorary Professor of Clinical Pharmacology at the University of Birmingham.

Back to top

Dr Frank McKenna BA MD FRCP, Appeal panel chair and NHS representative

Frank McKenna has been a member of the Appeal Committee since 2008. Dr McKenna is a Consultant Physician and Rheumatologist at Trafford General Hospital in Manchester and Honorary Clinical Lecturer at the University of Manchester. He examines for the MRCP (UK). He has had a lengthy contribution to medical management and has undertaken a number of roles including latterly that of operational medical director. He has a prolonged interest in clinical pharmacology of anti-rheumatic drug therapy. His active research interests are currently in biologic drug therapy and the role of sleep pathology in rheumatic diseases. He has represented the British Society for Rheumatology on several NICE appraisals for the treatment of rheumatoid arthritis and is treasurer for the BSR.

Back to top

Dr Anthony Emmerson BSc MD FRCP FRCPCH, NHS representative

Consultant Neonatologist, St Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust.

Dr Anthony Emmerson has been a consultant neonatologist since 1993. In the recent past, as Clinical Lead for the Neonatal Network and Medical Director of the Neonatal Intensive Care Partnership, he was instrumental in delivering the Making it Better reconfiguration of obstetric, neonatal and paediatric services across Greater Manchester. He has sat on the NICE Interventional Procedures Advisory Committee since 2012 and was involved with developing the quality standards for Hypertension in Pregnancy. He is a clinical advisor for the Parliamentary and Health Service Ombudsman. He has had a long standing interest in medical education and is Head of School of Paediatrics in the North Western Deanery. He has experience of appeals panels relating to training issues. He has research interests in neonatal care including vitamin D levels in newborn infants and is Medical Editor of the Journal Infant.

Back to top

Dr Ashutosh Wechalekar MD, FRCP, FRCPath, DM, NHS representative

UK National Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Campus, London, UK

Royal Free NHS Foundation Trust, London, UK

Ashutosh Wechalekar is a Senior Lecturer and Honorary Consultant Haematologist at University College London Medical School and the Royal Free London NHS Foundation Trust. He trained in haematology in UK and Canada. In 2004, he joined the UK National Amyloidosis Centre funded by a grant from Leukaemia research fund and is a consultant at the centre since 2007. He is a board member of UK Myeloma forum. He has been key in establishing the UK amyloidosis network and represents the network as a stakeholder in various forums. He is a member of the British Society haematology guidelines group for developing guidelines for treatment of multiple myeloma and AL amyloidosis. His clinical research has clarified the role of drugs like bortezomib in the treatment pathway for amyloidosis. His academic interests are focused on biomarkers in cardiac amyloidosis, novel imaging methods for the heart in all types of amyloidosis, characterization and treatment of systemic AL amyloidosis as well as multiple myeloma including clinical trials of new and novel agents in these disorders. He has published extensively in these areas.

Back to top

This page was last updated: 18 February 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.